Barclays Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $106

Benzinga Newsdesk www.benzinga.com Positive 89.4%

Neg 0% Neu 0% Pos 89.4%

Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price target from $95 to $106.